The global Gingivitis Treatment Market is expected to garner a market value of US$ 7 Billion in 2023 and is expected to accumulate a market value of US$ 11.19 Billion by registering a CAGR of 4.8% in the forecast period 2023 to 2033. The market for Gingivitis Treatment registered a CAGR of 3.2% in the historical period 2018 to 2022.
The gingivitis treatment market refers to the global market for products and services used to treat gingivitis, which is a common gum disease caused by inflammation of the gum tissue surrounding the teeth.
The market for gingivitis treatment is expected to grow significantly over the next few years due to the increasing prevalence of gum disease, rising awareness about oral health, and the introduction of innovative products and technologies for gingivitis treatment.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | US$ 7 Billion |
| Anticipated Forecast Value (2033) | US$ 11.19 Billion |
| Projected Growth Rate (2023 to 2033) | 4.8% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to market research and competitive intelligence provider, Future Market Insights- the market for Gingivitis Treatment reflected a value of 3.2% during the historical period, 2018 to 2022. There has been a growing awareness about the importance of oral health in recent years. Consumers are becoming more conscious of the link between oral health and overall health, leading to increased demand for oral care products and services. This trend is driving growth in the gingivitis treatment market as consumers seek out effective solutions for gum disease.
Furthermore, the rise of e-commerce and online sales channels is also driving growth in the gingivitis treatment market. Consumers are increasingly turning to online channels to purchase oral care products and services, which is creating new opportunities for companies operating in the market.
Overall, the market for Gingivitis Treatment is expected to register a CAGR of 4.8% in the forecast period 2023 to 2033.
Increasing Prevalence of Gingivitis to push market growth
One of the major factors driving growth in the gingivitis treatment market is the increasing prevalence of gum disease. According to the Centers for Disease Control and Prevention (CDC), nearly half of all adults in the United States have some form of gum disease. Similar trends are observed in other regions around the world, driving demand for effective treatment options.
Gingivitis is a common form of gum disease that causes inflammation and bleeding of the gums, and if left untreated, it can progress to more severe forms of gum disease. According to the World Health Organization, gingivitis is one of the most prevalent oral health issues worldwide, affecting up to 90% of the global population at some point in their lives.
The rising prevalence of gingivitis can be attributed to several factors, including poor oral hygiene, smoking, aging, and certain medical conditions that affect oral health. As the prevalence of gingivitis continues to increase, there is a growing demand for effective treatment options, which is expected to drive the growth of the gingivitis treatment market.
Furthermore, as the awareness of the link between oral health and overall health continues to grow, more people are seeking out treatment options for gingivitis to maintain good oral health and prevent other health issues. This is expected to further drive the growth of the gingivitis treatment market.
Overall, the increasing prevalence of gingivitis is expected to push the growth of the gingivitis treatment market, presenting opportunities for companies operating in the market to expand their offerings and capture market share.
In addition, the introduction of innovative products and technologies for gingivitis treatment is driving growth in the market. For example, the use of lasers for gum disease treatment has gained popularity in recent years due to its effectiveness and minimally invasive nature. Similarly, the development of new formulations and delivery mechanisms for oral care products is driving demand for these products.
Principal Consultant
Expensive Cost of Treatment to restrict Market Growth
Despite the growing awareness of the importance of maintaining good oral health, many people still lack awareness of gum disease and its treatment options. This can limit demand for gingivitis treatment products and services.
Additionally, the cost of gingivitis treatment can be a barrier for many people, particularly those without insurance coverage. This can limit demand for treatment options and make it more challenging for companies to generate revenue..
Companies operating in the gingivitis treatment market must comply with regulatory requirements related to product safety and efficacy. This can be challenging and costly, particularly for smaller companies without significant resources. Overall, companies operating in the gingivitis treatment market must navigate these challenges to capture market share and drive growth. By developing innovative products, building strong brands, and effectively communicating the benefits of their offerings, companies can overcome these challenges and succeed in this market.
Increasing awareness and diagnosis of the condition Shaping Landscape for Gingivitis Treatment in South & East Asia
The gingivitis treatment market in the South and East Asia region is growing rapidly due to several factors, including increasing awareness of oral health, rising disposable incomes, and the presence of a large population base.
Countries like China, India, Japan, and South Korea are some of the key markets for gingivitis treatment products in the region. These countries have a large population base, and a significant percentage of the population suffers from gum disease. As a result, there is a high demand for gingivitis treatment products in these markets.
In addition, increasing disposable incomes and growing awareness of the importance of oral health are driving demand for high-quality oral care products, including those used for gingivitis treatment. This has led to the introduction of new products and technologies in the market, including innovative toothpaste formulations, mouthwashes, and advanced dental instruments.
Overall, the gingivitis treatment market in the South and East Asia region is expected to continue to grow in the coming years, driven by increasing demand for oral care products and rising awareness of the importance of oral health.
Increasing Focus on Technological advancements Shaping Landscape for Gingivitis Treatment in North America
There is a growing awareness of the importance of oral health in North America, which is driving demand for gingivitis treatment products. People are becoming more aware of the links between gum disease and overall health, which is encouraging them to take better care of their teeth and gums.
There have been significant technological advances in gingivitis treatment products, including new toothpaste formulations, advanced dental instruments, and innovative oral care products. Dental insurance is widely available in North America, which makes it easier for people to access gingivitis treatment products and services. This is driving demand for these products and services, as people are more likely to seek treatment when they have insurance coverage.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Oral route of administration to hold a significant share and push market growth
The oral route of administration is likely to account for a significant share in the gingivitis treatment market. Oral gingivitis treatment products include tablets, capsules, and liquid formulations, which are ingested by patients to treat the condition. These products are convenient to use and offer systemic treatment, which can help to address the underlying causes of gum disease.
In addition, many oral gingivitis treatment products are available over-the-counter, which makes them easily accessible to patients. This convenience and accessibility are expected to drive demand for oral gingivitis treatment products in the market.
Retail pharmacies segment to hold a significant share and push market growth
The retail pharmacy segment is likely to account for a significant share in the gingivitis treatment market by distribution channel. Retail pharmacies are easily accessible to patients and offer a wide range of gingivitis treatment products, including over-the-counter and prescription medications. Patients can receive expert advice from pharmacists on the use of these products and their effectiveness in treating gum disease.
In addition, retail pharmacies offer the convenience of online ordering and home delivery, which has become increasingly popular in recent years. This convenience and accessibility are expected to drive demand for gingivitis treatment products through retail pharmacies.
Key players in the market include companies such as Fibrocell Sciences, Tolmar Inc., Eli Lilly & Company, Align Technology, Dentsply International, 3M Company, Ultradent Products Inc., Nobel Biocare Holdings AG, Glidewell Laboratories, Orapharma, Kaken Pharmaceutical, and Valeant Pharmaceuticals Int., along with healthcare providers and technology companies among other global players.
The technique involves a specialized probe and detector that provide quantitative measurements of biomarkers indicating the presence and severity of gum disease. These biomarkers were validated and identified by the university's Periodontal Research Group and published in the Journal of Clinical Periodontology earlier this year. The researchers have secured funding from the EPSRC Impact Acceleration Account to create a prototype of the device, which is expected to be launched within a year.
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | US$ 7 Billion |
| Market Value in 2033 | US$ 11.19 Billion |
| Growth Rate | CAGR of 4.8% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled | Fibrocell Sciences, Tolmar Inc., Eli Lilly & Company, Align Technology, Dentsply International, 3M Company, Ultradent Products Inc., Nobel Biocare Holdings AG, Glidewell Laboratories, Orapharma, Kaken Pharmaceutical, and Valeant Pharmaceuticals Int. |
| Customization | Available Upon Request |
The market is estimated to secure a valuation of US$ 7 billion in 2023.
The market is estimated to reach US$ 11.19 billion by 2033.
Retail pharmacy sector holds high revenue potential.
The United States, India, and China dominate the global market.
The market is forecast to register a CAGR of 4.8% through 2033.
1. Executive Summary | Gingivitis Treatment Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033
5.3.1. Veetids
5.3.2. Erythrocin
5.3.3. Minocycline
5.3.4. Doxycycline
5.3.5. Clindamycin
5.3.6. Chlorhexidine
5.3.7. Acetaminophen
5.3.8. Ibuprofen
5.3.9. Lidocaine
5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033
6.3.1. Oral
6.3.2. Topical
6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033
7.3.1. Hospital Pharmacy
7.3.2. Retail Pharmacy
7.3.3. Online Pharmacy
7.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022
7.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. South Asia
8.3.5. East Asia
8.3.6. Oceania
8.3.7. MEA
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. USA
9.2.1.2. Canada
9.2.2. By Drug Class
9.2.3. By Route of Administration
9.2.4. By End User
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Drug Class
9.3.3. By Route of Administration
9.3.4. By End User
9.4. Key Takeaways
10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Drug Class
10.2.3. By Route of Administration
10.2.4. By End User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Drug Class
10.3.3. By Route of Administration
10.3.4. By End User
10.4. Key Takeaways
11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. United kingdom
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Europe
11.2.2. By Drug Class
11.2.3. By Route of Administration
11.2.4. By End User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Drug Class
11.3.3. By Route of Administration
11.3.4. By End User
11.4. Key Takeaways
12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Malaysia
12.2.1.3. Singapore
12.2.1.4. Thailand
12.2.1.5. Rest of South Asia
12.2.2. By Drug Class
12.2.3. By Route of Administration
12.2.4. By End User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Drug Class
12.3.3. By Route of Administration
12.3.4. By End User
12.4. Key Takeaways
13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. South Korea
13.2.2. By Drug Class
13.2.3. By Route of Administration
13.2.4. By End User
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Drug Class
13.3.3. By Route of Administration
13.3.4. By End User
13.4. Key Takeaways
14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. Australia
14.2.1.2. New Zealand
14.2.2. By Drug Class
14.2.3. By Route of Administration
14.2.4. By End User
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Drug Class
14.3.3. By Route of Administration
14.3.4. By End User
14.4. Key Takeaways
15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. GCC Countries
15.2.1.2. South Africa
15.2.1.3. Israel
15.2.1.4. Rest of MEA
15.2.2. By Drug Class
15.2.3. By Route of Administration
15.2.4. By End User
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Drug Class
15.3.3. By Route of Administration
15.3.4. By End User
15.4. Key Takeaways
16. Key Countries Market Analysis
16.1. USA
16.1.1. Pricing Analysis
16.1.2. Market Share Analysis, 2022
16.1.2.1. By Drug Class
16.1.2.2. By Route of Administration
16.1.2.3. By End User
16.2. Canada
16.2.1. Pricing Analysis
16.2.2. Market Share Analysis, 2022
16.2.2.1. By Drug Class
16.2.2.2. By Route of Administration
16.2.2.3. By End User
16.3. Brazil
16.3.1. Pricing Analysis
16.3.2. Market Share Analysis, 2022
16.3.2.1. By Drug Class
16.3.2.2. By Route of Administration
16.3.2.3. By End User
16.4. Mexico
16.4.1. Pricing Analysis
16.4.2. Market Share Analysis, 2022
16.4.2.1. By Drug Class
16.4.2.2. By Route of Administration
16.4.2.3. By End User
16.5. Germany
16.5.1. Pricing Analysis
16.5.2. Market Share Analysis, 2022
16.5.2.1. By Drug Class
16.5.2.2. By Route of Administration
16.5.2.3. By End User
16.6. United kingdom
16.6.1. Pricing Analysis
16.6.2. Market Share Analysis, 2022
16.6.2.1. By Drug Class
16.6.2.2. By Route of Administration
16.6.2.3. By End User
16.7. France
16.7.1. Pricing Analysis
16.7.2. Market Share Analysis, 2022
16.7.2.1. By Drug Class
16.7.2.2. By Route of Administration
16.7.2.3. By End User
16.8. Spain
16.8.1. Pricing Analysis
16.8.2. Market Share Analysis, 2022
16.8.2.1. By Drug Class
16.8.2.2. By Route of Administration
16.8.2.3. By End User
16.9. Italy
16.9.1. Pricing Analysis
16.9.2. Market Share Analysis, 2022
16.9.2.1. By Drug Class
16.9.2.2. By Route of Administration
16.9.2.3. By End User
16.10. India
16.10.1. Pricing Analysis
16.10.2. Market Share Analysis, 2022
16.10.2.1. By Drug Class
16.10.2.2. By Route of Administration
16.10.2.3. By End User
16.11. Malaysia
16.11.1. Pricing Analysis
16.11.2. Market Share Analysis, 2022
16.11.2.1. By Drug Class
16.11.2.2. By Route of Administration
16.11.2.3. By End User
16.12. Singapore
16.12.1. Pricing Analysis
16.12.2. Market Share Analysis, 2022
16.12.2.1. By Drug Class
16.12.2.2. By Route of Administration
16.12.2.3. By End User
16.13. Thailand
16.13.1. Pricing Analysis
16.13.2. Market Share Analysis, 2022
16.13.2.1. By Drug Class
16.13.2.2. By Route of Administration
16.13.2.3. By End User
16.14. China
16.14.1. Pricing Analysis
16.14.2. Market Share Analysis, 2022
16.14.2.1. By Drug Class
16.14.2.2. By Route of Administration
16.14.2.3. By End User
16.15. Japan
16.15.1. Pricing Analysis
16.15.2. Market Share Analysis, 2022
16.15.2.1. By Drug Class
16.15.2.2. By Route of Administration
16.15.2.3. By End User
16.16. South Korea
16.16.1. Pricing Analysis
16.16.2. Market Share Analysis, 2022
16.16.2.1. By Drug Class
16.16.2.2. By Route of Administration
16.16.2.3. By End User
16.17. Australia
16.17.1. Pricing Analysis
16.17.2. Market Share Analysis, 2022
16.17.2.1. By Drug Class
16.17.2.2. By Route of Administration
16.17.2.3. By End User
16.18. New Zealand
16.18.1. Pricing Analysis
16.18.2. Market Share Analysis, 2022
16.18.2.1. By Drug Class
16.18.2.2. By Route of Administration
16.18.2.3. By End User
16.19. GCC Countries
16.19.1. Pricing Analysis
16.19.2. Market Share Analysis, 2022
16.19.2.1. By Drug Class
16.19.2.2. By Route of Administration
16.19.2.3. By End User
16.20. South Africa
16.20.1. Pricing Analysis
16.20.2. Market Share Analysis, 2022
16.20.2.1. By Drug Class
16.20.2.2. By Route of Administration
16.20.2.3. By End User
16.21. Israel
16.21.1. Pricing Analysis
16.21.2. Market Share Analysis, 2022
16.21.2.1. By Drug Class
16.21.2.2. By Route of Administration
16.21.2.3. By End User
17. Market Structure Analysis
17.1. Competition Dashboard
17.2. Competition Benchmarking
17.3. Market Share Analysis of Top Players
17.3.1. By Regional
17.3.2. By Drug Class
17.3.3. By Route of Administration
17.3.4. By End User
18. Competition Analysis
18.1. Competition Deep Dive
18.1.1. Fibrocell Sciences
18.1.1.1. Overview
18.1.1.2. Product Portfolio
18.1.1.3. Profitability by Market Segments
18.1.1.4. Sales Footprint
18.1.1.5. Strategy Overview
18.1.1.5.1. Marketing Strategy
18.1.2. Tolmar Inc.
18.1.2.1. Overview
18.1.2.2. Product Portfolio
18.1.2.3. Profitability by Market Segments
18.1.2.4. Sales Footprint
18.1.2.5. Strategy Overview
18.1.2.5.1. Marketing Strategy
18.1.3. Eli Lilly & Company
18.1.3.1. Overview
18.1.3.2. Product Portfolio
18.1.3.3. Profitability by Market Segments
18.1.3.4. Sales Footprint
18.1.3.5. Strategy Overview
18.1.3.5.1. Marketing Strategy
18.1.4. Align Technology
18.1.4.1. Overview
18.1.4.2. Product Portfolio
18.1.4.3. Profitability by Market Segments
18.1.4.4. Sales Footprint
18.1.4.5. Strategy Overview
18.1.4.5.1. Marketing Strategy
18.1.5. Dentsply International
18.1.5.1. Overview
18.1.5.2. Product Portfolio
18.1.5.3. Profitability by Market Segments
18.1.5.4. Sales Footprint
18.1.5.5. Strategy Overview
18.1.5.5.1. Marketing Strategy
18.1.6. 3M Company
18.1.6.1. Overview
18.1.6.2. Product Portfolio
18.1.6.3. Profitability by Market Segments
18.1.6.4. Sales Footprint
18.1.6.5. Strategy Overview
18.1.6.5.1. Marketing Strategy
18.1.7. Ultradent Products Inc.
18.1.7.1. Overview
18.1.7.2. Product Portfolio
18.1.7.3. Profitability by Market Segments
18.1.7.4. Sales Footprint
18.1.7.5. Strategy Overview
18.1.7.5.1. Marketing Strategy
18.1.8. Nobel Biocare Holdings AG
18.1.8.1. Overview
18.1.8.2. Product Portfolio
18.1.8.3. Profitability by Market Segments
18.1.8.4. Sales Footprint
18.1.8.5. Strategy Overview
18.1.8.5.1. Marketing Strategy
18.1.9. Glidewell Laboratories
18.1.9.1. Overview
18.1.9.2. Product Portfolio
18.1.9.3. Profitability by Market Segments
18.1.9.4. Sales Footprint
18.1.9.5. Strategy Overview
18.1.9.5.1. Marketing Strategy
18.1.10. Orapharma
18.1.10.1. Overview
18.1.10.2. Product Portfolio
18.1.10.3. Profitability by Market Segments
18.1.10.4. Sales Footprint
18.1.10.5. Strategy Overview
18.1.10.5.1. Marketing Strategy
18.1.11. Kaken Pharmaceutical
18.1.11.1. Overview
18.1.11.2. Product Portfolio
18.1.11.3. Profitability by Market Segments
18.1.11.4. Sales Footprint
18.1.11.5. Strategy Overview
18.1.11.5.1. Marketing Strategy
18.1.12. Valeant Pharmaceuticals Int.
18.1.12.1. Overview
18.1.12.2. Product Portfolio
18.1.12.3. Profitability by Market Segments
18.1.12.4. Sales Footprint
18.1.12.5. Strategy Overview
18.1.12.5.1. Marketing Strategy
19. Assumptions & Acronyms Used
20. Research Methodology
Explore Healthcare Insights
View Reports
Gingivitis Treatment Market
